Zusammenfassung
Hintergrund
In vorangehenden Studien zur präventiven Therapie von Patienten mit paroxysmalem Vorhofflimmern (VHF) wurde bifokale rechtsatriale Stimulation (BS) bei gleichzeitiger antiarrhythmischer Therapie als effektive Strategie zur Verlängerung des rezidivfreien Intervalls beschrieben. Die vorliegende Studie vergleicht prospektiv die kumulative Prävalenz von VHF (AF Burden) während unifokaler (US) und bifokaler rechtsatrialer Stimulation unter spiegelkontrollierter Sotaloltherapie.
Methoden
Bei 19 Patienten mit symptomatischer Sinusknotendysfunktion und paroxysmalem Vorhofflimmern wurde ein DDDR-Schrittmachersystem mit einer rechtsatrial lateralen und einer tief septal am Koronarsinusostium platzierten Vorhofsonde implantiert. Eine anhand des Plasmaspiegels kontrollierte Sotaloltherapie wurde begonnen. Nach einer dreimonatigen Phase mit zurückhaltender rein antibradykarder Stimulation (Back-up-Phase) wurden die Patienten für 3 Monate auf kontinuierliche rechtsatrial BS oder US randomisiert. Im Anschluss wurde für weitere 3 Monate der komplementäre Modus programmiert. Primärer Studienendpunkt war AF Burden. Als sekundäre Endpunkte wurden die Anzahl von Episoden, das rezidivfreie Intervall und die Therapiesicherheit definiert.
Ergebnisse
Während der Back-up-Phase trat zu 12,4% der Zeit und während US und BS zu je 6,2% Vorhofflimmern auf. (p = 0,91 US vs. BS, p = 0,08 Back-up vs. US und p = 0,07 Back-up vs. BS, "Intention- to-treat"-Analyse.) Auch die „per-protocol“-Analyse ergab keinen Vorteil für eine der beiden Stimulationskonfigurationen. (US 4,8% und BS 5,4% VHF, p = 0,64). Atriale Stimulation verminderte tendenziell die Vorhofflimmerlast im Vergleich zur Back-up-Phase (US oder BS 6,2% vs. Back-up 8,8%, p = 0,09). Bei 3 Patienten kam es zur Dislokation der atrial septalen Sonde.
Schlussfolgerung
Atriale Stimulation unter Sotaloltherapie reduziert tendenziell die Vorhofflimmerlast bei Patienten mit Sinusknotendysfunktion und paroxysmalem VHF. Ein zusätzlicher präventiver Effekt von BS vs. US kann nicht bestätigt werden. Rechtsatrial BS ist möglicherweise mit einer höheren Sondendislokationsrate verbunden.
Abstract
Aims
Bifocal right atrial pacing (BP) has been reported to increase arrhythmia-free intervals in patients with paroxysmal atrial fibrillation (PAF) under antiarrhythmic drugs. This study compares AF burden with unifocal pacing (UP) vs BP under sotalol.
Methods
In 19 patients with PAF a DDDR pacemaker with right atrial lateral and CS ostial leads was implanted. Sotalol was initiated. After a 3 month back-up pacing period patients were randomized to continuous UP or BP for 3 months and crossed over for 3 more months. Primary endpoint was AF burden. Secondary endpoints included number of episodes, time to first recurrence and safety of BP.
Results
The intention to treat analysis revealed 12.4% AF during back-up, 6.2% during UP and BP (p = 0.91 UP vs BP, p = 0.08 back-up vs UP and p = 0.07 back-up vs BP). Per protocol analysis showed no advantage of either pacing mode (UP 4.8% and BP 5.4% AF, p=0.64). Overdrive pacing reduced AF burden to 6.2 vs 8.8% during back-up (p=0.09). Septal lead dislodgement occurred in 3 patients.
Conclusion
Atrial pacing tends to reduce AF burden in patients with PAF under sotalol. An incremental effect of BP vs UP cannot be confirmed. BP may be complicated by elevated lead dislodgement rates.
References
Allessie M, Ausma J, Schotten U (2002) Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovascular Research 54:230–246
Arentz T, Ott P, von Rosenthal J et al (2003) Effect of atrial overdrive pacing on pulmonary vein focal discharge in patients with atrial fibrillation. Europace 5:25–31
Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D (1998) Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 98:946–952
Daubert C, Gras D, Berder V, Leclercq C, Mabo P (1994) Permanent atrial resynchronization by synchronous bi-atrial pacing in the preventive treatment of atrial flutter associated with high degree interatrial block. Arch Mal Coeur Vaiss 87 (Suppl):1535–1546
Delfaut P, Saksena S, Prakash A, Krol RB (1998) Long-term outcome of patients with drug refractory atrial flutter and fibrillation after single- and dual-site right atrial pacing for arrhythmia prevention. J Am Coll Cardiol 32:1900–1908
Duytschaever M, Danse P, Eysbouts S, Allessie M (2002) Is there an optimal pacing site to prevent atrial fibrillation? an experimental study in the chronically instrumented goat. J Cardiovasc Electrophysiol 13:1264–1271
Friberg J, Buch P, Scharling H et al (2003) Rising rates of hospital admissions for atrial fibrillation. Epidemiology 14:666–672
Gregoratos G, Abrams J, Epstein AE et al (2002) ACC/AHA/NASPE 2002 Guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article. A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). Circulation 106:2145–2161
Lau CP, Tse HF, Yu CM et al (2001) Dual-site atrial pacing for atrial fibrillation in patients without bradycardia. Am J Cardiol 88:371–375
Levy T, Walker S, Rex S, Rochelle J, Paul V (2001) No incremental benefit of multisite atrial pacing compared with right atrial pacing in patients with drug refractory paroxysmal atrial fibrillation. Heart 85:48–52
Michelucci A, Padeletti L, Fradella GA et al (1984) Effects of atropine on atrial refractoriness and its dispersion in humans. Int J Clin Pharmacol Ther Toxicol 22:254–258
Mirza I, James S, Holt P (2002) Biatrial pacing for paroxysmal atrial fibrillation a randomized prospective study into the suppression of paroxysmal atrial fibrillation using biatrial pacing. J Am Coll Cardiol 40:457–463
Misier AR, Opthof T, Van Hemel NM et al (1992) Increased dispersion of refractoriness in patients with idiopathic paroxysmal atrial fibrillation. J Am Coll Cardiol 19:1531–1535
Nielsen JC, Kristensen L, Andersen HR et al (2003) A randomized comparison of atrial and dual-chamber pacing in 177 consecutive patients with sick sinus syndrome. J Am Coll Cardiol 42:614–623
Prakash A, Delfaut P, Krol RB et al (1998) Regional right and left atrial activation patterns during single- and dual-site atrial pacing in patients with atrial fibrillation. Am J Cardiol 82:1197–1204
Rha S-W, Kim Y-H, Hong MK et al (2007) Mechanisms responsible for the initiation and maintenance of atrial fibrillation assessed by non-contact mapping system. Int J Cardiol doi:10.1016/j.ijcard.2007.02.013
Saksena S, Prakash A, Hill M et al (1996) Prevention of recurrent atrial fibrillation with chronic dual-site right atrial pacing. J Am Coll Cardiol 28:687–694
Saksena S, Prakash A, Ziegler P et al; for the DAPPAF Investigators (2002) Improved suppression of recurrent atrial fibrillation with dual-site right atrial pacing and antiarrhythmic drug therapy. J Am Coll Cardiol 40:1140–1150
Simpson RJ, Foster JR, Gettes LS (1982) Atrial excitability and conduction in patients with interatrial conduction defects. Am J Cardiol 50:1331–1337
Sweeney MO, Hellkamp AS, Ellenbogen KA et al (2003) Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation 107:2932–2937
Wattingney WA, Mensah GA, Croft JB (2003) Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention. Circulation 108:711–716
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Stockburger, M., Gerhardt, L., Helms, S. et al. Bifocal versus unifocal right atrial pacing under plasma level controlled sotalol to prevent atrial fibrillation in patients with symptomatic sinus bradycardia and paroxysmal atrial fibrillation. Herzschr. Elektrophys. 18, 250–258 (2007). https://doi.org/10.1007/s00399-007-0582-9
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s00399-007-0582-9